STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
February 2025 — Vol. 2, No. 2
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, February 2025The United Arab Emirates declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
A supplier suspends shipping to Portugal after 23 consecutive customs detentions
The route did not close because of a rule about peptides.
What changed at BCH in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Janoshik result on a Suzhou mazdutide lot lands 4.0 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
From the floor in Wuxi: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
JEEP declines, for the 23rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a GGPeps tirzepatide lot at 96.6%, against 93.7% on the certificate
The result is unremarkable. What the report omits is not.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
What a 31% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Hong Kong: 3 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Nigeria health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
Canada health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.